KPTI
Karyopharm Therapeutics Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Karyopharm Therapeutics Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Karyopharm Therapeutics has 1 disclosed supplier and 5 disclosed customers in SEC filings.
SentenceUnder the terms of the Original Antengene Agreement, we received an upfront cash payment of $11.7 million in 2018.
KPTI 10-Kaccession 0001193125-26-049397
We have retained the exclusive production rights and will supply finished product to FORUS for commercial use in Canada.
KPTI 10-Kaccession 0001193125-26-049397
SentenceWe received from Libo an upfront payment and a milestone payment upon completion of technology transfer and are entitled to receive development and regulatory milestones and single-digit royalties on future net sales of KPT-1200.
KPTI 10-Kaccession 0001193125-26-049397
SentenceLicense revenue included $15.0 million of revenue for the reimbursement of development related expenses from the Menarini Group ("Menarini").
KPTI 10-Kaccession 0001193125-26-049397
SentencePromedico received the exclusive rights to commercialize XPOVIO in the Promedico Territory and is responsible for all regulatory filings and obligations required for registering XPOVIO.
KPTI 10-Kaccession 0001193125-26-049397
Karyopharm Therapeutics Inc.
0.65
Linked news
Expected move
Inputsspot 0.66exp Nov 20ATM strike 0.5ATM straddle 0.42IV 398%